Special Issue "Pancreatic Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 November 2010) | Viewed by 467860
Interests: pancreas cancer; apoptosis; microarrays; signal transduction networks; tumor stroma interaction; prostate cancer; biomarker
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive malignancies in industrialized countries. It is characterized by early metastasis and aggressive, infiltrative growth along the endothelium basement membrane and neurons. However, in recent years the crucial genetic changes leading to pancreatic cancer have been indentified. Genetic analyses of patient samples have shown that the vast majority of those cancers display mutations in KRAS and the p16 locus. Despite these advancements PDAC shows an overall five-year survival rate of only 5%. Therefore new efforts have to be made in the field of translational oncology to improve the understanding, the diagnosis and the therapy of this disease.Apart from PDAC there are other pancreatic cancer types, which differ highly in patient outcome due to their tissue origin and genetic make up. Cancers like intraductal papillary mucinous neoplasia are of growing concern to the physicians and researchers in the field. This issue will focus on the recent key findings in the field of pancreatic cancer research and therapy. It will contain different articles regarding the different types of pancreatic cancer, the latest research and new strategies to improve the therapy of this disease.
Dr. Christian Pilarsky
- tumor suppressor gene
- gene function
- neoadjuvant therapy
- epithelial mesenchymal transition
- stem cells
- survival prediction